` EPIX (ESSA Pharma Inc) vs S&P 500 Comparison - Alpha Spread

EPIX
vs
S&P 500

Over the past 12 months, EPIX has underperformed S&P 500, delivering a return of -88% compared to the S&P 500's +12% growth.

Stocks Performance
EPIX vs S&P 500

Loading
EPIX
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
EPIX vs S&P 500

Loading
EPIX
S&P 500
Difference
www.alphaspread.com

Performance By Year
EPIX vs S&P 500

Loading
EPIX
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
ESSA Pharma Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

ESSA Pharma Inc
Glance View

Market Cap
9.5m USD
Industry
Biotechnology

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.

EPIX Intrinsic Value
Not Available
Back to Top